The Human PeptideAtlas is a compendium of the highest quality peptide identifications from over 1000 shotgun mass spectrometry proteomics experiments collected from many different laboratories, all reanalyzed through a uniform processing pipeline. The latest 2015−03 build contains substantially more input data than past releases, is mapped to a recent version of our merged reference proteome, and uses improved informatics processing and the development of the AtlasProphet to provide the highest quality results. Within the set of ∼20 000 neXtProt primary entries, 14 070 (70%) are confidently detected in the latest build, 5% are ambiguous, 9% are redundant, leaving the total percentage of proteins for which there are no mapping detections at just 16% (3166), all derived from over 133 million peptide-spectrum matches identifying more than 1 million distinct peptides using AtlasProphet to characterize and classify the protein matches. Improved handling for detection and presentation of single amino-acid variants (SAAVs) reveals the detection of 5326 uniquely mapping SAAVs across 2794 proteins. With such a large amount of data, the control of false positives is a challenge. We present the methodology and results for maintaining rigorous quality along with a discussion of the implications of the remaining sources of errors in the build.
■ INTRODUCTION
Shotgun mass spectrometry (MS) proteomics is still the most widely used workflow for identifying and quantifying large numbers of proteins in complex samples. In this workflow, proteins are digested into peptides, which are then separated via liquid chromatography and injected as charged ions into a mass spectrometer. 1 The instrument sequentially isolates these precursor ions, fragments them, and collects mass spectra of the fragment ions for each. These fragment ion spectra must then be subjected to complex informatics analysis to reconstruct the peptides that ultimately produced these spectra and then map the peptides to a reference proteome. 2 Since the first Human PeptideAtlas build in 2004, 3 the number of high confidence spectra in the resource has increased over 500-fold, and the number of distinct peptides nearly 40-fold. In previous articles, we have described this steady increase in coverage as well as new functionality for exploring the data. 4−7 As the number of available data sets has grown, we have created sub-builds for specific tissue or sample types. Last year's PeptideAtlas update for the Journal of Proteome Research (JPR) second C-HPP special issue focused on a comparison between three sample subtypes: kidney, urine, and blood plasma. 7 In addition to human builds, there are PeptideAtlas builds for many other important species including recent new builds for cow, 8 horse, 9 and C. albicans. 10 A key focus of the PeptideAtlas is maintaining a well-understood and carefully controlled false discovery rate (FDR) for the identifications contained therein. To achieve this objective, all data sets obtained by PeptideAtlas are researched and processed by the components of the Trans-Proteomic Pipeline (TPP), 11 a suite of tools for the analysis and validation of shotgun proteomics data.
The Human Proteome Project (HPP) is an international effort to advance our understanding of the human proteome in a multipronged approach that includes characterizing its individual components, creating capabilities to assay all those components, and understanding how the system driven by the proteome changes in states of wellness and disease.
PeptideAtlas has been a key component of the MS pillar of the HPP, providing the primary reference for peptides and proteins reliably detected by experiments produced by HPP participants and others throughout the community. It is the primary MS data source for neXtProt, 13 which serves as the primary HPP knowledgebase. An overview of what is contained in neXtProt and its sources has been provided yearly;
13,14 the current status is described elsewhere in this issue (Omenn et al., submitted for this issue).
Here we present the state of the Human PeptideAtlas for the period 2014/2015. Substantial increases in the numbers of spectra and distinct peptides were achieved, and the increase in the number of confidently identified proteins was 1044 distinct entries. In the following sections, we describe the latest enhancements to the PeptideAtlas build methodology, present the latest results from the August 2014 build and the March 2015 build, and discuss issues surrounding build quality and our analysis of false positives. In the JPR Call for Papers for this third C-HPP special issue, authors were instructed to use PeptideAtlas 2014−08 and neXtProt 2014−09−19 to facilitate comparisons of results.
■ METHODS
The creation of the August 2014 and March 2015 Human PeptideAtlas builds follows the same workflow that has been previously described, 4−6 with new and additional bioinformatic enhancements that are described in the following. Briefly, all input experiments are searched with one or more sequence search engines, typically X!Tandem 15 with the k-score plugin 16 and Comet 17 using a comprehensive sequence database that includes all of the UniProt 18, 19 Complete Proteome set with all single amino-acid variants (SAAVs) in UniProt expanded into sequence snippets appended to each protein, 14 additional IPI 20 proteins with uniquely mapping peptides that have passed threshold in previous IPI-based builds and map nowhere else, and the full set of cRAP common contaminant proteins from GPM. 21 The database is appended with a like-sized set of decoy sequences that was generated by keeping all tryptic cleavage sites fixed and shuffling the order of amino acids between the cleavage sites with the addition of a lookup hash used so that every distinct input peptide is always shuffled the same way to match redundancy in the target sequences. The results are then postprocessed with PeptideProphet 22 for each experiment separately, followed by additional modeling by iProphet 23 to combine the results from different search engines, further refine the probabilities, and assign robust probabilities to each PSM and distinct peptide sequence. These tools are designed to maximize the number of true positives and minimize the number of false positives that pass any applied threshold by considering all corroborating evidence for each PSM. The probability threshold is set individually for each data set to achieve a constant peptide FDR for each data set, and all PSMs passing the probability threshold are assembled into a master list including all the decoy hits. This master list is evaluated by MAYU 24 to calculate final PSM-level, peptidelevel, and protein-level FDRs. The PSM FDR threshold is then set to achieve an approximately 1% FDR at the protein level.
All peptides that are included in the build are then mapped to a more comprehensive sequence database that includes all of TrEMBL 27 and Ensembl 27 as well as all SAAVs catalogued in neXtProt, in addition to the sources mentioned previously. This allows easier exploration of the PeptideAtlas results using the Ensembl or TrEMBL accession number domains (in addition to neXtProt and UniProt accessions) and also enables us to map all peptides onto the human genome. Therefore, all peptides (those that map to Ensembl proteins) will have full genome coordinates in the database. In many cases, a peptide will span one or more introns, and thus two or more sets of coordinates are associated with different parts of the peptide. It is important to note that the August 2014 build is mapped to the GRCh37 genome assembly, while the March 2015 build is mapped to the GRCh38 genome assembly, which means there is a small difference between the coordinates of most peptides in the two builds. Table A significant change in the 2015−03 build is how the protein inference is performed. As previously described, in prior builds, all the resulting iProphet-written pepXML files for each experiment were analyzed with ProteinProphet 28 for the final protein inference step. This had the advantage that the ProteinProphet algorithm is widely used and well regarded as successful in applying parsimony rules to develop the shortest list of proteins that can explain the peptide evidence. However, it was primarily designed as a generic tool for the processing of individual data sets and has a few shortcomings in the context of building a consensus proteome from many hundreds of experiments.
Therefore, we have developed a custom inference tool, which we will refer to as AtlasProphet here, and which we used for this release but remains a work in progress at this time. After additional refinement, these new ideas will be released in a new publicly available version of ProteinProphet. The first innovation is how the AtlasProphet understands a reference proteome (i.e., the full list of proteins that the mass spectra are processed against). ProteinProphet treats all proteins in the reference proteome as equals, which results in cases where when two or more proteins share several peptides, the one with the most peptides will become the main high probability protein, and the others become subsumed. This leads to cases where a primary Swiss-Prot protein is labeled as subsumed to an isoform, TrEMBL, IPI, or Ensembl entry, or cases where a Swiss-Prot protein existence (PE) = 1 protein is listed as subsumed to a PE = 5 protein on account of one additional peptide that might be explainable in other ways. In contrast, AtlasProphet is fully aware of a rank of importance of the different reference protein sources in the database as listed in Table 1 , and will preferentially categorize proteins with a better rank as canonical and categorize other proteins in a worseranked source relative to the canonical. This scheme is a major revision of the Cedar scheme we published previously, 5 which does already have some elements of Swiss-Prot entries outranking entries from other databases. Briefly, the process of the AtlasProphet is to load the reference proteome, assign rankings to proteins according to Table 1 , load all peptides and their protein mappings, group together all proteins that share peptides, and then assign each of the proteins within each group a category based on its relationship to other proteins in the group, taking into account the unicity of all peptides in the group along with the protein category assignments.
PeptideAtlas uses the PE values as reported by neXtProt and Swiss-Prot but does not alter them. Briefly, PE = 1 means that the protein entry has been deemed by a set of rules or a curator of one of the two knowledgebases as being reliably observed in its translated form. PE = 2 means that a transcript from the gene has been observed in human samples, and there is every expectation that the protein is translated. PE = 3 means that the protein entry has a homologue in another species where it has been reliably detected. PE = 4 means that credible bioinformatic predictions suggest that the protein is translated. PE = 5 means that curators have deemed that the entry likely corresponds to a pseudogene that is not translated, but weak historical evidence has thus far prevented the entry from being completely deleted. While the majority of PE classifications between neXtProt and UniProtKB are the same, there are some differences because the two knowledgebases have some differing data sets as evidence.
In Table 1 , the first column is the priority rank of each source of proteins. These ranks are used for resolving ties for protein categorization as described in the following. A lower number indicates a better rank. Fractional ranks are used to differentiate ranking that is already present in some of the sources. For example, neXtProt/UniProt already has a PE ranking system, as described previously, where a lower number represents a better rank as well. We have accommodated PE ranks within our system by dividing the PE value by 10 and adding the result to our rank numbers. Therefore, a neXtProt 20k entry with a PE = 2 will have a rank of 1.2. This means that higher PE values will give a protein entry a worse rank. Note that varsplic (isoform) entries do not have PE values assigned to them. We also note that all Swiss-Prot entries that are specifically excluded from neXtProt (primarily very old entries corresponding to immunoglobulin variable regions) are ranked worse than sequences included in neXtProt, irrespective of PE value. These entries are slated to be replaced in the future. The second column is the name of the source of proteins. The third column indicates the number of proteins from that source that were used as our references for the 2015−03 build. These numbers will change for future builds as our use of annotations within these sources improves. The final column provides a specific description of each source. It is important to note that while our search database does not include Table 1 , ranks 5 and 6 (TrEMBL not Complete Proteome, and Ensembl), we do add them to the mapping database. There are very few detectable peptides in these two sources that are not already contained in the other groups, but we include them by community requests so that all passing peptides can be seen mapping directly to these namespaces. In response to other community requests, we will also begin mapping to the RefSeq source of proteins with the next release and will assess if mapping directly to GENCODE sequences would also be beneficial.
The term isoform is used to refer to one of several possible protein sequence variations derived from the same gene as listed in neXtProt and Swiss-Prot. These are usually different splice isoforms but may also be extensions or shortened forms. Single amino acid changes, PTMs, or other post-translational processing such as signal peptide cleavage are not included as isoforms. Previous builds have mapped to all IPI proteins directly. Since the IPI set has now been long deprecated, we no longer map to this set; however, there is a small number of peptides with high probability that map to 14 IPI accessions and nowhere else. These have been retained until these discrepancies can be resolved, either as false positives or bona f ide annotations that should be included in the reference knowledgebases. For example, IPI01022236 appears to be a splice isoform of P07437, which currently has no varsplic isoform entries and whose alternate splicing junctions are well supported by multiple peptides. This evidence has been sent to neXtProt for inclusion in future releases. We anticipate that once these discrepancies are resolved, no more IPI entries will remain in future PeptideAtlas builds.
Another innovation in the 2015−03 build is a refinement of the protein categories since previously published by Farrah et al. 5 A few additional categories are now organized within four groups as shown in Table 2 to make their detection status more precise and more understandable. The four major groups are canonical, ambiguous, redundant, and not observed (column 1). Column 2 lists the new categories as well as the groups into which the categories are sometimes aggregated. The canonical group is the set of proteins that are deemed high confidence detections, although they should not be considered without errors (see Discussion of error rates below). The ambiguous group contains proteins of various more specific categories that denote that while they contain one or more peptides that might be correct evidence of their detection, there are complications (beyond poor PSMs) that indicate that they cannot qualify for canonical yet. The redundant group includes various categories that indicate that a protein has no uniquely mapping peptides, and therefore, while the protein may truly have been detected, the evidence peptides map to multiple proteins. Therefore, the protein does not belong in a parsimonious list. The table provides a detailed description of the meaning of each protein category within these groups. The difference between identical and indistinguishable categories is that identical proteins have exactly the same sequence and are therefore either reference duplicates or, if originating from different chromosomal loci, impossible to differentiate based on sequence and would be discarded if not for the desire to view all accessions as entries in the atlas. Indistinguishable proteins cannot be distinguished with the available evidence, but since they do differ in predicted sequence, they could possibly be distinguished with additional evidence; the potential of suitable tryptic peptides for distinguishing purposes is not considered here. In cases where two or more proteins compete for identical rank, the alphanumerically lower accession wins over higher accessions, with the exception that for UniProt-style accessions, those that begin with P win over Q, which wins over all others. For example, following the order P12345 > P34567 > Q12345 > A12345 > B12345 > B34567, if P12345 and P34567 were identical in sequence, P34567 would always be categorized identical and P12345 some higher category; if they were both different in sequence but indistinguishable, P34567 would be indistinguishable (redundant), and P12345 would be the indistinguishable representative (ambiguous) (or weak or insufficient evidence if appropriate).
In this new scheme, we have introduced crucial, though arbitrary, qualifiers including the number and length of uniquely mapping peptides. Whereas in previous builds, even a single seven-AA peptide was sufficient to categorize a protein as canonical, there must now be at least two uniquely mapping peptides of length 9. The length limitation has been introduced to overcome the fact that very short peptides can often receive very high scores based on a few spurious peaks plus the fact that short peptides are more likely to be not truly uniquely mapping despite the fact that our imperfect understanding of the human reference proteome (including variants of all types) would imply that they are. PeptideAtlas has for a long time rejected peptides of length 6 and below for this problem. Now that the Human PeptideAtlas has topped 1 million peptides and 100 million PSMs, we have found that peptides of length 7 and 8 are exhibiting this problem as well. PeptideAtlas and neXtProt both share a commitment to ensuring the highest quality mass spectrometric evidence for annotations of proteins, but there is still some difference in the details of these acceptance thresholds between PeptideAtlas canonical and neXtProt PE = 1, as discussed in Omenn et al. (submitted, this issue).
We also decided it is logical to require at least two distinct peptides before elevating a protein to canonical since a single hit within such a vast amount of data brings a certain level of suspicion. In future builds, we may consider making an exception for proteins where it seems likely that only one or two peptides are amenable for detection based on standard methods, and those exact expected peptides are detected. However, while two distinct peptides are required, these two peptides are allowed to be partially sequence overlapping. While having overlapping peptides generally brings confidence that neither identification is due to random noise, there is some danger that both identifications suffer from the same homology-based misidentification (see the following for further discussion about these types of errors).
While nearly all of the proteins in the PeptideAtlas are classified in an automated manner using the workflow described previously, some (but not all) of the more unlikely identifications, such as those of PE > 1 and weak or insufficient evidence in the PeptideAtlas classification, have been examined manually. In cases where the PSM is determined to be either incorrect or of insufficient quality to be confident in its accuracy, the PSM is marked as rejected. If all PSMs corresponding to a protein are marked as rejected, then the protein itself is automatically put in the "rejected" category. Whenever a spectrum is marked as not being credible evidence for a specific peptide sequence, it remains so labeled for all future builds as well, although additional evidence can alter the protein category. There are, of course, too many spectra for curators to examine all of them, but it is worthwhile and in fact important to examine manually the evidence for single-hit proteins and proteins that are previously annotated in neXtProt as not having definitive protein evidence to ensure that the automated statistical scoring is performing as expected and at the same time discard obviously incorrect or insufficiently convincing PSMs. While PeptideAtlas curators have not yet examined most of the spectra supporting lower-evidence proteins, all spectra are easily accessible to everyone and can be viewed using the Lorikeet spectrum viewer or downloaded for additional examination.
■ RESULTS

Overall Build Results
The results of the August 2013, August 2014, and March 2015 Human PeptideAtlas builds are summarized in Table 3 . The 2014 and 2015 builds are derived from processing over 400 million MS/MS spectra from ∼100 000 MS runs and contain Table 3 Because the Reference Is Different over 100 million high-quality PSMs, 1.0 million distinct peptide sequences, and over 14 000 distinct proteins at the target threshold of 1% FDR at the protein level. To achieve this level of stringency, the PSM-level FDR is approximately 0.00009, and the peptide-level FDR is 0.0003. Between the 2014 and 2015 builds, the number of PSMs has increased by over 15 million. Yet, fewer than 4000 new distinct peptides were added. Of the 1.0 million distinct peptides, only about 300 are expected to be false positives based on our calculated peptidelevel FDR. The total number of canonical proteins went down because of the new strategy for classifying proteins as described previously. There are three notable differences in the reference proteome: neXtProt has been added as the highest level of the reference; in addition to the UniProt "Complete Proteome" set (UniProtCP), all of the rest of TrEMBL has now been added; nearly all of the IPI database has been removed except for the 14 "orphan" sequences as described previously.
The number of proteins claimed depends significantly on the reference proteome used and the criteria used to claim a confident detection. The strategy for doing this within PeptideAtlas has evolved over time. Although there were not a lot of new data added between the August 2014 and March 2015 builds, the method of counting proteins did change significantly, as described in the Methods section. While Table  3 lists the total number of canonical proteins derived from the merged reference proteome, the numbers in Table 4 are limited to the subset of proteins listed in neXtProt, which is a smaller list (not including, for example, immunoglobulins, orphan IPI proteins, etc.). Table 4 lists the number of proteins in the various categories for both the 2014−08 and 2015−03 builds. In contrast, there were a lot of data added between 2013 and 2014 as presented in the following. The overall number of canonical proteins is lower for the 2015−03 build because proteins with less certain evidence were moved to different categories (in the ambiguous group). The total number of proteins for which there are no detected peptides was reduced by 2%, reducing the total percentage of proteins for which there are no mapping detections at all to just 16% (3166) of the 20 061. These numbers differ somewhat from the HPP "missing proteins" in that the HPP "missing proteins" are a combination of not-observed proteins, some ambiguous proteins, and explicitly do not include the PE = 5 proteins (see Omenn et al. in this issue).
We compared the total PSM and peptide counts in the latest PeptideAtlas build with those from the latest National Institute of Standards and Technology (NIST) spectral libraries (http:// peptide.nist.gov) and the summary of GPMDB (http://gpmdb. thegpm.org/statistics_species.html). The NIST libraries have ∼208 000 distinct peptides in the ion trap library and ∼433 000 distinct peptides in the union of the high-resolution MS/MS libraries. There are ∼69 000 distinct peptides contained in the NIST libraries that are not in PeptideAtlas (∼12 000 of these are for peptides of length 6 or below, which are automatically discarded by PeptideAtlas), while ∼606 000 peptides are not present in the NIST libraries. See Supplementary Figure 1 of the Supporting Information for a Venn diagram depicting the overlap between PeptideAtlas and the NIST libraries. The GPMDB 21 claims 1.5 billion peptide observations for human samples, which is 10-times larger than the number of PSMs in PeptideAtlas, but the stringency is lower, with low-quality PSMs matching to nearly every protein.
The raw data, either in mzML or raw instrument format, for the experiments used here are available in the PeptideAtlas raw data repository (http://www.peptideatlas.org/repository/) along with the search results and TPP tool output. For very large experiments where the raw data are already accessible in another repository, the raw data are not duplicated in the PeptideAtlas raw data repository interface. The results of the build process are available in the build download area (http:// www.peptideatlas.org/builds/) in several different formats.
Contribution of New Data Sets
Since the 2013 Human PeptideAtlas build last described, 7 there has been considerable addition of new data sets. The four most notable large tranches of data that have been added come from the CPTAC Consortium, 29 which extensively analyzed TCGA Project (http://cancergenome.nih.gov) tumors in several different facilities, the Pandey Lab, 30 which analyzed 24 different adult and fetal tissue samples and six cell types (publicly available under accession PXD000561), the Kuster Lab, 31 which analyzed 36 different adult normal tissues (publicly available under accession PXD000865, although their Web site also includes results from numerous other data sets not produced by their lab under that accession), and the Mirzaei Lab, 32 which analyzed HeLa cells with combinations of seven different enzymes for the digestion step. Figure 1 depicts the impact that these four tranches of data have had on the PeptideAtlas between 2013 and 2015. The number of distinct peptide sequences in the Human PeptideAtlas build doubled from less than 0.5 million to ∼1 million. However, the contribution to the number of neXtProt 20k proteins categorized as canonical added was far more modest, increasing from 13 026 to just 14 070. Together these data sets have significantly increased the sequence coverage of proteins already included and added another ∼8% proteins. However, this is a rather small increase considering the tremendous amount of data that was added and the much larger numbers of proteins claimed to have been identified in refs 30 and 31 due in large part to the rejection of application of an FDR threshold at the protein level and use of quite lax FDR filters for PSM and peptide levels (see Omenn et al. in this issue).
Sample Categories and Sample-Specific Builds
In addition to the full proteome builds described previously, there are 20 tissue/fluid specific builds, such as for brain, kidney, lung, plasma, and urine. Each of these builds based on human tissue contains only a subset of samples specific for the tissue or biofluid; data derived from cultured cell lines are not included in these sample-specific builds so as not to create artificial tissue proteomes. For these builds, the same process described previously is used, but the input data set list is limited to those of each sample type. There is also an "Other" build that includes all other samples not included in the 20 selected sample types. Each of these builds maintains a threshold so that each has a protein-level FDR of 1%. However, it is very important to note that aggregating all these individual builds will not precisely equal the main build because the PSM-level thresholds set in the build process are quite different. Since there are fewer data in each of the individual sample builds, the probability threshold can be lower to achieve the same desired protein-level FDR. These sample-specific builds should be used when one wants to compare a set of proteins observed in one sample type versus another or if a specific research question is best limited within one sample type. Users should be warned that aggregating several or all of these builds will yield a much higher FDR. If one wishes to limit or categorize entries in the main build by sample type, there is a query option that allows one to filter the result by sample type.
One important change in the most recent Human all-sample PeptideAtlas builds is that they are no longer vastly dominated by normal tissue/biofluid samples and cell line samples. These latest builds now contain a very large number of high-quality spectra from tumor-derived samples from the CPTAC consortium analyzed by the latest generation LTQ Orbitrap Velos and Q Exactive MS instruments.
At the PeptideAtlas Web site at http://www.peptideatlas. org/hupo/c-hpp/ is a listing of the number of proteins by chromosome, by PE level, and by category. The tabular data are available for both the 2014−08 build and the 2015−03 build. These results are summarized by AtlasProphet protein category in Figure 2 . Ultimately, these categories are intended to answer the question "Is a specific protein of interest detected in PeptideAtlas?". If the questioner wants a black and white answer, then "canonical" or not is the answer. If a more nuanced answer is desirable, then the four groups outlined in Figure 2 may be used as the answer. Approximately 70% of the neXtProt 20 061 protein entries are listed as canonical. Another 5% are categorized as ambiguous for a variety of reasons as discussed previously, including 70 indistinguishable representatives. Another 9% have peptides that map to them but only in a nonunique manner and therefore are not needed to explain any peptides and are not needed in a parsimonious list of proteins. Finally, there are still 16% of the proteins among the neXtProt 20k that have no peptides at all that pass our stringent quality criteria. The most nuanced answer to the question of the presence of a protein in PeptideAtlas is one of the 10 categories in Table 2 . Of course, at lower probability thresholds, some additional proteins would have correct identifications, but other protein entries would gather false identifications at an even faster rate.
Support for Single Amino Acid Variants
The existence of SAAV-containing peptides is often overlooked in proteomics data analyses, although it is gaining additional attention in the context of the analysis of proteomics data in conjunction with RNA-seq (see review 33). However, many SAAVs are already known and curated in UniProt and neXtProt, and PeptideAtlas now has partial support for SAAVs contained in those resources. UniProt currently contains over 70 000 human SAAVs, while neXtProt curates over 1.1 million SAAVs from various sources. Thus, far, the 1011 human experiments (for PeptideAtlas, an experiment is a single sample irrespective of possible prefractionation, and thus usually includes several MS runs) in PeptideAtlas have been sequence searched against a database containing the 70 000 UniProt SAAVs as described in the Methods section. Therefore, most of the SAAVs listed in UniProt could have been discovered given sufficiently high quality PSMs. In some cases, a peptide can be discovered via its existence in the search database and even appear to be uniquely mapping therein; however, when mapped to a much larger space of a great number of known SAAVs, it is sometimes the case that the peptide is no longer uniquely mapping. To guard against these cases, all identified peptides are mapped to an expansion of the full list of neXtProt SAAVs. Using this methodology, we have identified apparent evidence in the data contained in PeptideAtlas for a total of 10 039 distinct SAAV entries for neXtProt SAAVs. Of these, 5326 sites have uniquely mapping peptides within 2794 neXtProt proteins. For the rest, there is some ambiguity in the mapping of the peptides; in some cases, a peptide can map to one protein with a SAAV and another protein in its reference form. Of note is a subset of ∼400 SAAVs for which the curated variant is seen almost exclusively because the reference genome, GRCh 38, itself constructed from a very small number of individuals, is in fact the rare variant. This reveals the underappreciated circumstance that several hundred peptides in widely observed proteins are not routinely detected in proteomics experiments unless SAAVs are properly handled because the reference genome and proteome used are based on a rare variant.
To enable users to explore the SAAV information in PeptideAtlas, we have added two interface extensions. First, in the protein view page, when there are any known Swiss-Prot or neXtProt variants, a new section is displayed, listing each of these variants. These variants are primarily SAAVs but also include signal peptides, propeptides, and other variations not explicitly curated as a separate entry (i.e., splice isoform). The SAAVs that are detected are displayed first before those not detected. An example is shown as Figure 3 for the human MMS19 nucleotide excision repair protein homologue (Q96T76). Of its 11 SAAVs listed in Swiss-Prot, four are detected and listed first. The display can be switched to the neXtProt list of SAAVs, which may yield a greater number. The dbSNP identifiers are listed for each entry when available. By clicking on the hyperlink in the second column, one can see on a separate web page a full listing of all peptides that support the reference sequence or the SAAV sequence.
A 34 at the exclusively seen SAAV corresponding to dbSNP entry rs2275586, one finds that at position chr10:97481001, the overall frequency of the reference sequence is only ∼4%, while ∼96% of genotypes analyzed for inclusion in the Kaviar database version 2.0 have the A → G forms (Supplementary Figure 2) . certain criteria. An example screenshot is available as Supplementary Figure 3 . Hyperlinks enable further examination of the evidence supporting the original sequence as well as the variations, both as tabular identification information and ultimately as individual annotated spectra. Frequency information for each of the variants may be explored via hyperlinks to the Kaviar database. 34 
■ DISCUSSION PeptideAtlas Quality Metrics
The stated quality metric of all PeptideAtlas builds for the last five years has been a 1% FDR at the protein level using a target/decoy strategy; the HUPO HPP adopted this same threshold as a guideline from its initiation. To achieve this protein FDR, the PSM-and peptide-level FDR thresholds must be far lower. This has the unfortunate effect of discarding many correct identifications, but this is necessary to limit the number of incorrect identifications in the set. Such a trade-off between false positives and false negatives is well-recognized in statistics. Further, as the size of a data compendium grows, the disparity between the PSM-level FDR and the protein level FDR grows wider. It is crucial to note that the 1% FDR is calculated for the entire build as a whole, not individual experiments. If each experiment were filtered at 1% FDR and then the results combined, nearly every protein in the proteome would have hits to it, and the combined result would have a far higher FDR. 35 However, while a 1% FDR at the protein level sounds satisfyingly low when stated in that way, with ∼15 000 nonredundant proteins in the build, this means there are ∼150 incorrectly identified proteins in the build, which may seem less satisfyingly low. This same calculation of multiplying the FDR times the population can show why a 1% peptide-level FDR with 1 million peptides and a 1% PSM-level FDR with 133 million PSMs will yield an unacceptable number of false positives that would easily cover most of the proteome. Nearly every PSM going into the build atlas has a very high probability, and there seems little leverage left in individual PSM probabilities to push for even higher quality. It is very rare to see poor-looking PSMs in the latest human build. However, manual inspection of proteins that are unlikely to be present (never before reported, or "one-hit wonders", especially with a single spectrum or short peptide) reveals that some PSMs with very high scores and that appear to be outstanding matches may nonetheless still be incorrect. It may be that manual inspection will be more effective in reducing the FDR rather than applying even more stringent probability thresholds at the PSM level.
Recently a new "picked" FDR algorithm was advanced for very large heterogeneous data sets. 25 It was reported to outperform a "classic" target-decoy FDR strategy, but it is not clear whether it outperforms the MAYU algorithm or the R Factor approach, 26 which both provide corrections to the "classic" FDR approach. We have had good experience with the MAYU algorithm and have used it for these builds. However, we will assess whether the "picked" FDR approach yields a different or better result in the next human build.
Olfactory Receptors as a Quality Test
It was recently reported by Ezkurdia et al. 36 that olfactory receptors (ORs) may make a useful test set of proteins for evaluating data sets if no tissue samples expected to have such proteins are included. Two recent compendia of MS/MS data 30, 31 were examined manually by Ezkurdia et al. with the conclusion that no credible PSMs for ORs could be verified 36 out of 108 and 200 claimed matches, respectively. These two data sets (reprocessed by our pipeline) are included in the latest PeptideAtlas in addition to many other data sets. None of the sample types entering the PeptideAtlas seem to be likely to harbor ORs. We have therefore examined the OR entries in PeptideAtlas to assess the quality of the build and determine if there are any credible detections of ORs. The output of the pipeline for the 2015−03 build yielded zero OR proteins categorized as canonical, zero categorized as indistinguishable representative, and three categorized as weak from a total of 425 ORs listed as neXtProt entries.
These identifications were examined carefully to see if the PSM evidence seemed motivating for claiming detection of these proteins. I3L273 has a single phosphopeptide PSM of good quality (Supplementary Figure 4) but may well better match an unknown highly homologous peptide and does not seem strong enough evidence to claim detection of this protein. Q9H255 also has just one PSM, and the spectrum is certainly not of sufficiently high quality for a convincing match. Q8NGI9 has two apparently excellent PSMs for the same semitryptic peptide, but upon very close inspection, the spectrum can be better explained by a slightly altered sequence, which may be a variant of lactotransferrin (Supplementary Figure 5a,b) . In the end, all three of these nonredundant detections are not definitive and have been rejected. We therefore conclude that none of the data sets included in PeptideAtlas contains high quality spectra derived from OR proteins. There were three stated detections (although in the "weak" category) significantly lower than our stated 1% protein-level FDR. This lends support to the postulate that the quality of a compendium of MS/MS data derived from samples not expected to contain ORs may be evaluated by counting the number of putative OR detections. There are reports that ORs may be functional in non-neural cell types, and transcripts have been claimed for a few ORs in nonneural samples suggesting that some proteins annotated as ORs may be annotated incorrectly, or the proteins may have other functions in other tissues. In any case, to claim that any OR has been detected in proteomic samples, more compelling evidence should be required. The August 2013 PeptideAtlas build did have two OR canonical entries (gene entries), both of which have now been reclassified and removed after similar manual scrutiny.
Largest Sources of Errors
Misidentification to a Highly Homologous Peptide Ion. Because of the stringent threshold used to build the latest atlas, poor PSMs are no longer the greatest source of errors. Rather, two new sources of error have emerged. The first is PSMs that are of very high quality and receive an outstanding score but instead should have been matched to a very similar peptide but with an unconsidered mass modification or sequence variation. An example of this kind discovered while reviewing evidence for PE = 5 proteins is the peptide EITALAPSIMK, which appears to be uniquely mapping to and therefore implicate the existence of protein POTEKP, a PE = 5 putative beta-actin-like protein. A PSM for this peptide (Supplementary Figure 6) is outstanding, with only one y2 ion missed. However, careful inspection of the spectrum reveals that it is of such high quality that there is no reason to justify the missing y2, and there is a nearby unexplained peak. If one maps the peptide EITALAPSTMK, where the K has been dimethylated, one finds a perfect match with no missed peaks (Supplementary Figure 7) . This dimethylation is likely to derive from sample handling rather than inherent dimethylation of the intact protein in the original specimen. The peptide EITALAPSTMK maps directly to actin itself, and that peptide has been observed 63 000 times in PeptideAtlas without the dimethylation. This is a classic case of an almost-correct identification entering the analysis result because the completely correct answer was not in the search space. Although we describe this single example in a recent tumor tissue analysis set, further evaluation has identified that ∼1% of total peptide identifications were methylated to various levels raising important issues regarding confidence not only in identification of peptides, but also in quantitation, especially for low abundance proteins, which are being identified as candidate biomarkers.
Misidentification of a Protein Despite a Correct Peptide Identification. The second largest case of error now is where the PSM is correct but is mapped to the incorrect protein, usually on account of an unconsidered SAAV or other variant. Peptides of length 6 AA or lower have always been discarded in PeptideAtlas because of this problem. Even if correctly identified, there is too much opportunity for the peptide to map to a different protein with unconsidered variants, including I/L substitutions as well as Q/K and N/D substitutions, which can be difficult to distinguish at low resolution or lax tolerances. Now that there are over 1 million distinct peptides, including over 45 000 distinct peptides of length 7, we find that most of these peptides map to several proteins, often via known SAAVs that we have now considered. Many of the ones that still do appear to map uniquely to an otherwise undetected protein are likely to map instead to a more common protein via an unconsidered variant. Investigators performing searches for "missing proteins" should specifically consider such SAAV explanations before claiming the missing proteins to have been detected. Comparison of fragmentation spectra for 2+ ions of peptide YFNPCYATAR in protein Q9UJA2. Top: high resolution HCD spectrum using an Orbitrap Velos from a fetal testis sample 30 in PeptideAtlas. Bottom: high resolution CID spectrum from a synthetic peptide using a 6530 QTOF. Despite being from different instruments and sources, the spectra are very similar, lending great confidence that the peptide has been correctly identified. Most of the unlabeled low-mass ions are immonium ions and other annotatable fragments.
An important issue that bears further investigation is the possibility that immunoglobulins, with their huge potential variability, may be an explanation of such single-hit proteins. Although there are 126 immunoglobulin variable region entries that are included in PeptideAtlas and our search databases (although specifically excluded from neXtProt), these SwissProt entries are very old and do not capture the full variability potential present in immunoglobulins. Therefore, there may be a significant number of entries in PeptideAtlas where the peptide is surely correctly identified, but the peptide is not uniquely mapping for the protein as implied by the current reference proteome because it can also be found in an immunoglobulin. This effect is almost surely present, but its scale is currently not known. We have begun working with the IMGT database 37 to expand our reference list of immunoglobulins and hope to have a more complete set of immunoglobulins in future PeptideAtlas releases.
Confirmation of Spectra Using Synthetic Peptides
For proteins with few supporting peptides, a positive match against the spectrum of a corresponding synthetic peptide provides substantially increased confidence in the available evidence. SRMAtlas 38, 39 is the largest compendium of spectra for synthetic peptides for several species including human. Comparison of spectra in the Human PeptideAtlas versus spectra from synthetic human tryptic peptides contained in the SRMAtlas provides solid evidence to peptide identities, although care must be taken to ensure that compared spectra use similar fragmentation mechanisms.
As an example, protein Q9UJA2 Cardiolipin synthase is a PE = 2 predicted protein with only two distinct peptides that map to it in the 2015 PeptideAtlas. One (AAAFYVR) is only 7 AAs long, is semitryptic in this protein, and maps to another much better observed protein in a fully tryptic manner; thus, there is no good reason to use this as evidence for the detection of Q9UJA2. The other peptide (YFNPCYATAR) maps uniquely to this protein and its one known isoform. A single uniquely mapping peptide is normally not very definitive evidence for a protein. However, a comparison between the HCD spectrum of the peptide in PeptideAtlas and a QTOF spectrum of the corresponding human synthetic peptide reveals a nearly perfect match (Figure 4) , lending great confidence that the peptide is correctly identified. However, there is still a possibility that the peptide derives from a different protein (such as an immunoglobulin as discussed above) in a manner that is not currently understood. An examination of the protein sequence reveals all other potential tryptic peptides fall into regions of the protein not likely to be observed (such as the signal sequence or transmembrane regions) or are too long, too short, or too extreme in hydrophobicity. The peptide YFNPCYATAR is the only one that has no reasons not to be seen, thereby lending significant confidence that this single-peptide protein identification is genuine.
■ CONCLUSION
We have presented the current state of the PeptideAtlas in August 2014 and March 2015, which represents a substantial improvement over previous builds. It includes several additional large-scale publicly accessible data sets, which double the total number of distinct peptides in the Human PeptideAtlas and increase the number of canonical neXtProt proteins by 1044 since 2013 (Figure 1) . In addition to including more data, we have enhanced the scheme by which we categorize proteins based on the available evidence.
There still remain over 3000 proteins for which there is no peptide evidence that pass our threshold in PeptideAtlas, including all of the 425 OR proteins and over 500 PE = 5 entries, which are thought to be pseudogenes or other nontranscribed and nontranslated genes. Of the rest, some may also not be translated, some are not suitable for detection with bottom-up proteomics using conventional digestion enzymes, and still others may be of such low abundance or only abundant under highly unusual conditions that detection is extremely difficult. 14 PeptideAtlas will continue to expand and improve in the coming years as increases in depth of MS experiments become available. More data sets will be added as they are made available in ProteomeXchange 40 repositories for shotgun data such as PRIDE and MassIVE.
Everyone in the community is encouraged to support this effort by submitting their raw spectra, metadata, and experimental results to ProteomeXchange. New and old data sets will be researched with an improved search strategy that considers more SAAVs, PTMs, splice variants, and predicted proteins in the search space. There will be more extensive manual curation to better understand the sources of error and reduce the FDR even further. There will also be improved support for data sets that have been digested with an enzyme other than trypsin, which until very recently has been rare. With these enhancements, PeptideAtlas will continue to advance as it has for the past 12 years as the most comprehensive compendium of the highest quality identifications produced from the shotgun proteomics experiments made public by the research community. to putative POTEPK peptide EITALAPSIMK with an oxidized methionine and iTRAQ modifications, and the same spectrum matched (more likely correctly) to actin peptide EITA-LAPSTMK with iTRAQ modifications plus an additional dimethylation on the lysine. The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jproteome.5b00500.
